SG11201806433VA - Composition and combined medication method for treating enterovirus infection - Google Patents

Composition and combined medication method for treating enterovirus infection

Info

Publication number
SG11201806433VA
SG11201806433VA SG11201806433VA SG11201806433VA SG11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA
Authority
SG
Singapore
Prior art keywords
composition
enterovirus infection
combined medication
medication method
treating
Prior art date
Application number
SG11201806433VA
Other languages
English (en)
Inventor
Gang Zou
Ralf Altmeyer
Yizhuo Wang
Original Assignee
Institut Pasteur Of Shanghai Chinese Academy Of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610067164.5A external-priority patent/CN105688216B/zh
Priority claimed from CN201610067175.3A external-priority patent/CN105664166B/zh
Application filed by Institut Pasteur Of Shanghai Chinese Academy Of Sciences filed Critical Institut Pasteur Of Shanghai Chinese Academy Of Sciences
Publication of SG11201806433VA publication Critical patent/SG11201806433VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/00021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/085Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201806433VA 2016-01-29 2017-01-11 Composition and combined medication method for treating enterovirus infection SG11201806433VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610067164.5A CN105688216B (zh) 2016-01-29 2016-01-29 治疗肠道病毒感染的组分和联合用药方法
CN201610067175.3A CN105664166B (zh) 2016-01-29 2016-01-29 一种治疗肠道病毒感染的组合物和联合用药方法
PCT/CN2017/070858 WO2017128950A1 (zh) 2016-01-29 2017-01-11 一种治疗肠道病毒感染的组合物和联合用药方法

Publications (1)

Publication Number Publication Date
SG11201806433VA true SG11201806433VA (en) 2018-08-30

Family

ID=59397381

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806433VA SG11201806433VA (en) 2016-01-29 2017-01-11 Composition and combined medication method for treating enterovirus infection

Country Status (6)

Country Link
US (1) US10864210B2 (ja)
JP (1) JP6644917B2 (ja)
AU (1) AU2017210921B2 (ja)
MY (1) MY201019A (ja)
SG (1) SG11201806433VA (ja)
WO (1) WO2017128950A1 (ja)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145608B (zh) * 2011-12-07 2015-09-02 南开大学 抗肠病毒71(ev71)己内酰胺类化合物及其制备方法和用途
CN105688216B (zh) * 2016-01-29 2019-01-25 中国科学院上海巴斯德研究所 治疗肠道病毒感染的组分和联合用药方法
CN105664166B (zh) * 2016-01-29 2019-05-10 中国科学院上海巴斯德研究所 一种治疗肠道病毒感染的组合物和联合用药方法

Also Published As

Publication number Publication date
JP6644917B2 (ja) 2020-02-12
AU2017210921A1 (en) 2018-08-16
WO2017128950A1 (zh) 2017-08-03
JP2019509331A (ja) 2019-04-04
US20190030027A1 (en) 2019-01-31
AU2017210921B2 (en) 2020-01-02
MY201019A (en) 2024-01-30
US10864210B2 (en) 2020-12-15

Similar Documents

Publication Publication Date Title
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
PH12016501379A1 (en) Azepane derivatives and methods of treating hepatitis b infections
MX2019010404A (es) Compuestos sulfamida cíclicos y métodos de uso de los mismos.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2019007256A (es) Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
MX2020004060A (es) Metodos para el tratamiento de infeccion de hepatitis b.
MX2016016722A (es) Coronavirus.
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2021007602A (es) Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b.
MX2021004464A (es) Compuestos de tiazolida para el tratamiento de infecciones virales.
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
EP3681508A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF VIRAL INFECTION
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
EP3658679C0 (en) METHOD FOR THE RAPID DETECTION AND COUNTING OF VIRUSES, BACTERIOPHAGES AND/OR BACTERIA
PH12017502386B1 (en) Methods of purification and/or viral inactivation
MX2021006326A (es) Inhibidores de pcna.
PH12017550047B1 (en) Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus